Literature DB >> 12500029

ETA, mixed ETA/ETB receptor antagonists, and protein kinase C inhibitor prevent acute hypoxic pulmonary vasoconstriction: influence of potassium channels.

Françoise Goirand1, Marc Bardou, Pascal Guerard, Jean-Paul Dumas, Luc Rochette, Monique Dumas.   

Abstract

The aims of this study were to investigate the effects of a selective ETA (BQ-123), a selective ETB (BQ-788), and a specific mixed ETA/ETB receptor antagonist (bosentan) on the pulmonary vasoconstriction induced by hypoxia in the isolated perfused rat lung, and the role of nitric oxide, adenosine triphosphate-sensitive (KATP), large conductance Ca+-activated (BKCa) and 4-aminopyridine-sensitive voltage-gated K channels (K+) in the relaxant effects of the selective ETA receptor antagonist BQ-123 and a protein kinase C inhibitor, bisindolylmaleimide I. K+ channels were inhibited by glibenclamide, charybdotoxin, and 4-aminopyridine and nitric oxide synthase by L-NG-nitroarginine methyl ester (L-NAME). Hypoxic ventilation produced a significant pressure response (+57%, p < 0.001). BQ-123, bosentan, and bisindolylmaleimide I induced a concentration-dependent decrease of the hypoxic pressure response (p < 0.001), whereas BQ-788 did not exhibit any inhibitory effect against hypoxic pressure response. Glibenclamide, charybdotoxin, and 4-aminopyridine partially opposed the inhibitory effects elicited by BQ-123 (p < 0.05), but L-NAME did not modify these effects. The effects of bisindolylmaleimide I on hypoxic pressure response were unaffected by glibenclamide, charybdotoxin, or 4-aminopyridine. The authors conclude that (a) ETA receptors and protein kinase C are involved in the modulation of hypoxic pulmonary vasoconstriction; and (b) the ETA antagonist BQ-123 opposes hypoxic pulmonary vasoconstriction through KATP, KV, and BKCa channels, differing in this from the protein kinase C inhibitor bisindolylmaleimide I. These results suggest that BQ-123 operates through a mechanism independent of bisindolylmaleimide I-inhibited protein kinase C isoforms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12500029     DOI: 10.1097/00005344-200301000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

Review 1.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

2.  Homology modeling, active site prediction, and targeting the anti hypertension activity through molecular docking on endothelin - B receptor domain.

Authors:  Daddam Jayasimha Rayalu; Chandrabose Selvaraj; Sanjeev Kumar Singh; Ramakrishan Ganeshan; Nagapatla Udaya Kumar; Panthangi Seshapani
Journal:  Bioinformation       Date:  2012-01-20

Review 3.  Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Abdirashit Maripov; Djuro Kosanovic; Norbert Weissmann; Hossein Ardeschir Ghofrani; Akpay Sh Sarybaev; Ralph Theo Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-02-10       Impact factor: 3.390

4.  Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms.

Authors:  Qing Miao; Xiao-Peng Shi; Ming-Xiang Ye; Jin Zhang; Shan Miao; Si-Wang Wang; Bo Li; Xiu-Xiu Jiang; Song Zhang; Nan Hu; Juan Li; Jian Zhang
Journal:  Int J Mol Sci       Date:  2012-06-21       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.